Uses of NANOG inhibitors and related methods
AssigneeUniversite De Geneve
InventorAriel Ruiz Altaba
Life of this patent
Estimating the term…
Abstract
The present invention relates to substances and compositions thereof useful in the control of cancer stem cell persistence and concomitant tumor recurrence and/or control of tumor growth. In particular, the invention relates to substances and compositions useful in the treatment of cancers and/or tumors linked to cancer stem cells, preferably brain cancers and/or tumors, in a subject.
Claims17
A NANOG antagonist that is a NANOG dominant-negative polypeptide comprising a NANOG homeodomain fused to the repressor domain of a heterologous protein.
A method of repressing or treating cancers linked to cancer stem cells in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of a NANOG antagonist selected from:
- a) a NANOG dominant-negative polypeptide comprising a NANOG homeodomain fused to the repressor domain of a heterologous protein;
- b) a vector driving the expression of said NANOG antagonist;
- or
- c) a pharmaceutical formulation comprising a) or b).
A method of controlling cancer stem cell persistence and concomitant tumor recurrence in a subject comprising administering to a subject in need thereof an amount of a NANOG antagonist selected from:
- a) a NANOG dominant-negative polypeptide comprising a NANOG homeodomain fused to the repressor domain of a heterologous protein;
- b) a vector driving the expression of said NANOG antagonist;
- or
- c) a pharmaceutical formulation comprising a) or b).
A method of repressing or treating cancers linked to cancer stem cells in a subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of a NANOG antagonist, wherein said NANOG antagonist is
- a) a short hairpin RNA selected from:
- i) shNANOG1 of nucleotide sequence SEQ ID NO:11,
- ii) shNANOG2 of nucleotide sequence SEQ ID NO:12 or
- iii) shNANOGP8 consisting of SEQ ID NO:13;
- b) a vector driving the expression of said NANOG antagonist;
- or
- c) a pharmaceutical formulation comprising a) or b).
A method of controlling cancer stem cell persistence and concomitant tumor recurrence in a subject comprising administering to a subject in need thereof an amount of a NANOG antagonist, wherein said NANOG antagonist is
- a) a short hairpin RNA selected from:
- i) shNANOG1 of nucleotide sequence SEQ ID NO:11,
- ii) shNANOG2 of nucleotide sequence SEQ ID NO:12 or
- iii) shNANOGP8 consisting of SEQ ID NO:13;
- b) a vector driving the expression of said NANOG antagonist;
- or
- c) a pharmaceutical formulation comprising a) or b).
Dependencies are inferred from the claim text.